Expert
Science
Health

We are a global pharmaceutical company
whose goal is to provide the best,
innovative and unique solutions for medicine.

We already deliver our products to 50 countries around the world, and our ambition is to become a global leader, setting trends and benchmarks in the Life Science industry.

Our work is based on scientific and health knowledge. Along with our expert approach, it allows us to create reliable and unique products.

We are constantly developing our competences. One of our leading achievements is on advancing field of immunotherapy. We manufacture one of the few drugs used internationally in the oncological immunotherapy of bladder cancer.

We have also created an anti-tuberculosis vaccine, which is used to vaccinate all newborns in the country. It is widely used all over the world.

Scientific knowledge and many years of experience in the cultivation of bacterial strains have allowed us to create one of the best probiotics on the market - Lakcid®, which is one of the few probiotic drugs available in the world.

Our goal is to create an effective, modern and dynamically developing organization in the Life Science industry. We already deliver our drugs to nearly 50 countries around the world, and our ambition is to become a global leader, setting trends and benchmarks on the market.

We are a Polish pharmaceutical company with almost 100 years of tradition, and constantly looking for new ways of development. Many years of experience and achievements of the company are the best proof of our commitment, the beneficiaries of which are our business partners and patients themselves.

Our Strategy

Vision
Mission and values

Expert at Delivering
Science for Better Health

SYNTHAVERSE is a company whose DNA determines the synthesis of ideas and approaches to pharmacy in order to seek breakthrough innovations that push the boundaries of medicine.

SYNTHAVERSE is a symbol of our commitment to science and technology, that shape the future of medicine, that reflect the needs of our business partners and patients.

SYNTHAVERSE is a leader in its industry that creates the future and cares for the health of the present and generations.

We use our expertise to explore science and combine versatile ideas to develop and deliver solutions, shaping global health.

Although we work together in Teams, we remember we are all part of the one Company team, and we support each other to achieve mutual success.

Teamwork

T
We encourage personal growth to gain competence at all we do.

Expertise

E
We want to create an environment where new ideas are welcomed; all ideas can be challenged.

Creativity

C
We are comfortable to respectfully say what we think.

Honesty

H
TECH – technology that delivers science, shaping global health.

Quality

Our biological medicines meet the strictest standards dedicated to the medicinal products market.

We operate basing on Good Manufacturing Practice (GMP), which is a set of requirements regarding production aspects and quality control tests, which, combined with monitoring the safety of pharmacotherapy (Pharmacovigilance), allow the production and trade of medicinal products of appropriate quality and ensure the highest safety of use in therapy.

Sterile products

Non-sterile products

Our History

We are a Polish pharmaceutical company with almost 100 years of tradition, and constantly looking for new ways of development.

Many years of experience and achievements of the company are the best proof of our commitment, the beneficiaries of which are our business partners and patients themselves.

See how we have changed over the years!

1944

Opening of the Typhoid Vaccine Production Laboratory and the Serum and Vaccine Production Plant at the NIH Branch in Lublin.

Production begins, including vaccines against:

 

  • rabies,
  • dysentery,
  • typhoid fever,

and the sera:

 

  • anti-diphtheria
  • anti-tetanus.
 

1951

The Department is separated from the structures of the National Institute of Hygiene and since then we have been operating as the Lublin Serum and Vaccine Factory.

 

1959

Two more breakthrough drugs for health protection are developed - the production of the polio vaccine (the virus that causes Heine-Medina disease) is launched and we start the production of the Lakcid® bacterial preparation.

1960

The Lublin Production Plant of Serums and Vaccines changes its name. Since then, we have been operating as the Serum and Vaccine Factory in Lublin.

1966

We are constantly working on improving our medicines. This year, Lakcid has been enriched with 3 more mutants, thus gaining resistance to neomycin, erythromycin and tetracycline.

1967

We register and start the production of Distreptaza, another important drug constituting a breakthrough therapy, this time in the field of gynecology and proctology.

1973

The production plant introduces the most modern production technology that allows to obtain 100% sterility in the preparation of bacterial suspensions for the production of probiotics.

1985-1988

The Lublin Factory introduces new technologies to improve serial production, and also starts research work together with the Central Laboratory of Vaccines and Serums in Warsaw on antibiotic resistance.

1988-1990

The right technology is finally developed and a new medicinal preparation named Lakcid Forte is produced, containing four times more Lactobacillus rhamnosus than Lakcid.

1994

The plant celebrates the 50th anniversary of the establishment of the plant. Our most important products are:

  • tuberculosis vaccine,
  • Lakcid,
  • Biogonadil,
  • Thrombin,
  • Gastrothrombin,
  • Histaglobin.

1999

After several years of efforts, the privatization process is completed. An employee-owned company called "Biomed", a Serum and Vaccine Factory LLC in Lublin, is established.

2001

Research work with the Department of Microbiology at the Jagiellonian University Medical College in Krakow resulted in a breakthrough increase in the resistance of Biomed's probiotics to as many as 27 groups of antibiotics.

2004

Introduction to the market of a new probiotic medicinal product Lakcid L.

2010- 2011

In 2010, the legal form of the enterprise was changed to a joint-stock company. A year later, on July 9, Biomed-Lublin enters the alternative market of the Warsaw Stock Exchange - NewConnect.

In the same year, the Main Pharmaceutical Inspectorate grants Biomed a GMP certificate in the field of manufacturing processes.

2012-2014

We register other extremely important plasma-like products: albumin, human coagulation factor VIII, and human normal immunoglobulin for intravenous administration.

2015

The company's debut on the Warsaw Stock Exchange. On January 30, BIOMED-LUBLIN issues its first shares on the main market.

2019-2020

We are starting a new, groundbreaking investment in the development of our own Research and Development Center (CBR), co-financed by PARP.

2021

We are launching another extremely important investment - the construction of a commercial line for the production of Onko BCG, an innovative drug against bladder cancer, which is an alternative and supplement to chemotherapy.

2023

The company focuses on development and creates a new strategy, which is accompanied by rebranding. Since then it has been known as the Synthaverse.